PMC7512221_01
a-c 18F-FDG PET/CT, performed for pancreatic neuroendocrine tumour, showed bilateral sub-segmental areas of ground glass opacities (purple arrows; SUVmax range 3.7-4). The patient had local recurrence in the paraaortic region and liver metastasis (orange arrow). Panel a: transaxial co-registered CT; Panel b: transaxial and sagittal fused PET/CT; Panel c: 18F-FDG Maximum Intensity projection (MIP). d-f 68 Ga-DOTATOC PET/CT show no uptake in lung lesion (purple arrow). The patient had local recurrence in the paraaortic region (orange arrow). Panel d: transaxial co-registered CT; Panel e: transaxial and sagittal fused PET/CT; Panel f: 68 Ga-DOTATOC Maximum Intensity projection (MIP)
40336_2020_388_Fig2_HTML.jpg
PMC7512221_01_40336_2020_388_Fig2_HTML.jpg
Fig2
Moreover, 18F-FDG PET/CT examination presented bilateral sub-segmental areas of ground glass opacities (GGO) in the lungs with increased [18F]-FDG uptake, while no pleural and mediastinal lymph nodes involvement was observed (Fig. 2a-c). These lung lesions showed no uptake in 68 Ga-DOTATOC PET/CT (Fig. 2d-f).
PMC7512221_02
a-c 18F-FDG PET/CT, performed for vesical urothelial cancer, showed lung opacities with mild uptake in subpleural right basal region and in the middle lobe were present (purple arrows; SUVmax range 3.6-4). Panel a: transaxial CT; Panel b: transaxial, coronal and sagittal fused PET/CT; Panel c: Maximum Intensity projection (MIP). d-f 18F-FDG PET/CT, performed for sepsi-endocarditis, performed after a 12-h fast and a pre-scan, showed mild interstitial consolidation-thickening (purple arrows; SUVmax range 3.8-4.3). Panel d: transaxial co-registered CT; Panel e: transaxial and sagittal fused PET/CT; Panel f: Maximum Intensity projection (MIP)
40336_2020_388_Fig3_HTML.jpg
PMC7512221_03_40336_2020_388_Fig3_HTML.jpg
Fig3
While 18F-FDG PET/CT did not show any endocarditis sign, we found hypermetabolic lungs opacities at the lingula and the right pulmonary base and hypermetabolic mediastinal lymph nodes (Fig. 3d-f).
PMC7512221_03
a-c 18F-FDG PET/CT, performed for vesical urothelial cancer, showed lung opacities with mild uptake in subpleural right basal region and in the middle lobe were present (purple arrows; SUVmax range 3.6-4). Panel a: transaxial CT; Panel b: transaxial, coronal and sagittal fused PET/CT; Panel c: Maximum Intensity projection (MIP). d-f 18F-FDG PET/CT, performed for sepsi-endocarditis, performed after a 12-h fast and a pre-scan, showed mild interstitial consolidation-thickening (purple arrows; SUVmax range 3.8-4.3). Panel d: transaxial co-registered CT; Panel e: transaxial and sagittal fused PET/CT; Panel f: Maximum Intensity projection (MIP)
40336_2020_388_Fig3_HTML.jpg
PMC7512221_03_40336_2020_388_Fig3_HTML.jpg
Fig3
While 18F-FDG PET/CT did not show any endocarditis sign, we found hypermetabolic lungs opacities at the lingula and the right pulmonary base and hypermetabolic mediastinal lymph nodes (Fig. 3d-f).
PMC7512221_04
a-c 18F-FDG PET/CT, performed for incidental lung lesion identified in a pre-surgical CT, showed an increased uptake in the speculated lung lesion (orange arrow; SUVmax 4.5) and multiple and diffuse GGO with increased metabolism (purple arrows; SUVmax range 5.8-7). Panel a: transaxial co-registered CT; Panel b: transaxial fused PET/CT; Panel c: Maximum Intensity projection (MIP). d-f 18F-FDG PET/CT, performed to assess suspected lung cancer spread, showed a 5 cm lung lesion with mediastinal lymph nodal involvement, right adrenal metastasis, multiple bone lesions (orange arrows) and crazy paving pattern in the lung with increased FDG uptake (purple arrows; SUVmax range 4.6-5). Panel d: transaxial co-registered CT; Panel e: transaxial and sagittal fused PET/CT; Panel f: Maximum Intensity projection (MIP)
40336_2020_388_Fig4_HTML.jpg
PMC7512221_05_40336_2020_388_Fig4_HTML.jpg
Fig4
Moreover, 18F-FDG PET/CT showed crazy paving pattern in the lung with increased [18F]-FDG uptake (Fig. 4d-f).
PMC7512221_05
a-c 18F-FDG PET/CT, performed for incidental lung lesion identified in a pre-surgical CT, showed an increased uptake in the speculated lung lesion (orange arrow; SUVmax 4.5) and multiple and diffuse GGO with increased metabolism (purple arrows; SUVmax range 5.8-7). Panel a: transaxial co-registered CT; Panel b: transaxial fused PET/CT; Panel c: Maximum Intensity projection (MIP). d-f 18F-FDG PET/CT, performed to assess suspected lung cancer spread, showed a 5 cm lung lesion with mediastinal lymph nodal involvement, right adrenal metastasis, multiple bone lesions (orange arrows) and crazy paving pattern in the lung with increased FDG uptake (purple arrows; SUVmax range 4.6-5). Panel d: transaxial co-registered CT; Panel e: transaxial and sagittal fused PET/CT; Panel f: Maximum Intensity projection (MIP)
40336_2020_388_Fig4_HTML.jpg
PMC7512221_05_40336_2020_388_Fig4_HTML.jpg
Fig4
Moreover, 18F-FDG PET/CT showed crazy paving pattern in the lung with increased [18F]-FDG uptake (Fig. 4d-f).
PMC7512221_06
a-c 18F-FDG PET/CT, performed for re-staging of DLBCL, showed multifocal peripheral GGO with increased FDG uptake (purple arrows; SUV max 13). Panel a: transaxial co-registered CT; Panel b: transaxial and sagittal fused PET/CT; Panel c: Maximum Intensity projection (MIP). d-f 18F-FDG PET/CT, performed for follow-up of squamous cell carcinoma of the tonsil, showed multilobar peripheral GGO in both lungs with increased metabolism (purple arrows; SUVmax range 5.3-6). Panel d: transaxial co-registered CT; Panel e: transaxial and sagittal fused PET/CT; Panel f: Maximum Intensity projection (MIP)
40336_2020_388_Fig5_HTML.jpg
PMC7512221_07_40336_2020_388_Fig5_HTML.jpg
Fig5
A 71-year-old male underwent 18F-FDG PET/CT during the follow-up of oropharynx cancer treated with combined chemo-radiotherapy (cT2cN1). 18F-FDG PET/CT was negative for tumor relapse but revealed multilobar peripheral GGO in both lungs with increased metabolism (SUV max 6), strongly suggesting for COVID-19 pneumonia (Fig. 5d-f).
PMC7512221_07
a-c 18F-FDG PET/CT, performed for re-staging of DLBCL, showed multifocal peripheral GGO with increased FDG uptake (purple arrows; SUV max 13). Panel a: transaxial co-registered CT; Panel b: transaxial and sagittal fused PET/CT; Panel c: Maximum Intensity projection (MIP). d-f 18F-FDG PET/CT, performed for follow-up of squamous cell carcinoma of the tonsil, showed multilobar peripheral GGO in both lungs with increased metabolism (purple arrows; SUVmax range 5.3-6). Panel d: transaxial co-registered CT; Panel e: transaxial and sagittal fused PET/CT; Panel f: Maximum Intensity projection (MIP)
40336_2020_388_Fig5_HTML.jpg
PMC7512221_07_40336_2020_388_Fig5_HTML.jpg
Fig5
A 71-year-old male underwent 18F-FDG PET/CT during the follow-up of oropharynx cancer treated with combined chemo-radiotherapy (cT2cN1). 18F-FDG PET/CT was negative for tumor relapse but revealed multilobar peripheral GGO in both lungs with increased metabolism (SUV max 6), strongly suggesting for COVID-19 pneumonia (Fig. 5d-f).